"Anti-Arrhythmia Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
| Descriptor ID |
D000889
|
| MeSH Number(s) |
D27.505.954.411.097
|
| Concept/Terms |
Anti-Arrhythmia Agents- Anti-Arrhythmia Agents
- Agents, Anti-Arrhythmia
- Anti Arrhythmia Agents
- Antiarrhythmic Drugs
- Drugs, Antiarrhythmic
- Antiarrhythmia Agents
- Agents, Antiarrhythmia
- Antiarrhythmia Drugs
- Drugs, Antiarrhythmia
- Anti-Arrhythmia Drugs
- Anti Arrhythmia Drugs
- Drugs, Anti-Arrhythmia
- Anti-Arrhythmics
- Anti Arrhythmics
Cardiac Depressants- Cardiac Depressants
- Depressants, Cardiac
- Myocardial Depressants
- Depressants, Myocardial
|
Below are MeSH descriptors whose meaning is more general than "Anti-Arrhythmia Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Arrhythmia Agents".
This graph shows the total number of publications written about "Anti-Arrhythmia Agents" by people in this website by year, and whether "Anti-Arrhythmia Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 2 | 1 | 3 |
| 2000 | 3 | 0 | 3 |
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 2 | 4 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 3 | 0 | 3 |
| 2008 | 0 | 2 | 2 |
| 2010 | 2 | 3 | 5 |
| 2011 | 8 | 2 | 10 |
| 2012 | 2 | 4 | 6 |
| 2013 | 3 | 3 | 6 |
| 2014 | 7 | 4 | 11 |
| 2015 | 3 | 2 | 5 |
| 2016 | 6 | 2 | 8 |
| 2017 | 2 | 5 | 7 |
| 2018 | 2 | 2 | 4 |
| 2019 | 3 | 2 | 5 |
| 2020 | 0 | 4 | 4 |
| 2021 | 3 | 6 | 9 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 4 | 4 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Arrhythmia Agents" by people in Profiles.
-
Efficacy of etripamil nasal spray for acute conversion of supraventricular tachycardia: a network meta-analysis. Cardiol J. 2024; 31(4):640-642.
-
Dronedarone for the Treatment of Atrial Arrhythmias in Adults With Congenital Heart Disease. Tex Heart Inst J. 2024 Apr 30; 51(1).
-
Safety and Efficacy of Intravenous Sotalol Following Congenital Heart Surgery. JACC Clin Electrophysiol. 2024 01; 10(1):135-136.
-
Paroxysmal atrial fibrillation ablation with a novel temperature-controlled CF-sensing catheter: Q-FFICIENCY clinical and healthcare utilization benefits. J Cardiovasc Electrophysiol. 2023 12; 34(12):2493-2503.
-
Nonresponse to Heart?Failure?Therapy: An Important Trajectory. JACC Heart Fail. 2023 06; 11(6):729-732.
-
Atrioventricular Nodal Ablation Is Not an Effective Treatment Strategy in Catecholaminergic Polymorphic Ventricular Tachycardia. Tex Heart Inst J. 2023 05 01; 50(3).
-
Kinase Inhibitors and Atrial Fibrillation: Mechanisms of Action and Clinical Implications. JACC Clin Electrophysiol. 2023 04; 9(4):591-602.
-
Arrhythmogenic cardiomyopathy is under-recognized in end-stage pediatric heart failure: A 36-year single-center experience. Pediatr Transplant. 2023 03; 27(2):e14442.
-
Clinical Predictors of Recurrent Supraventricular Tachycardia in Infancy. J Am Coll Cardiol. 2022 09 20; 80(12):1159-1172.
-
A Case of Infantile Mitochondrial Cardiomyopathy Treated with a Combination of Low-Dose Propranolol and Cibenzoline for Left Ventricular Outflow Tract Stenosis. Int Heart J. 2022 Sep 30; 63(5):970-977.